Literature DB >> 1379134

Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope.

M Ohlin1, J Hinkula, P A Broliden, R Grunow, C A Borrebaeck, B Wahren.   

Abstract

Human MoAbs of IgM class were developed against three regions of the HIV-1 envelope. Uninfected donor lymphocytes were immunized in vitro with recombinant protein pB1. Four out of five antibodies were directed to different parts of the V3 region, which contains a major neutralizing site. Two out of these antibodies were directed to more than one amino acid sequence, indicating reactivity to discontinuous sites. Two of the human MoAbs inhibited viral spread between cells in tissue culture, interpreted as reactivities to conserved amino acid sequences exposed during viral maturation. No MoAb neutralized virus, which may be explained by the relatively low avidity of the antibodies. One MoAb was directed to a region containing amino acids participating in CD4 binding. This technique appears to allow formation of antibodies with fine specificities other than those obtained in infected hosts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379134      PMCID: PMC1554443          DOI: 10.1111/j.1365-2249.1992.tb06947.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  52 in total

Review 1.  Strategy for the production of human monoclonal antibodies using in vitro activated B cells.

Authors:  C A Borrebaeck
Journal:  J Immunol Methods       Date:  1989-10-24       Impact factor: 2.303

2.  Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus.

Authors:  L A Evans; J M Homsy; W J Morrow; I Gaston; C D Sooy; J A Levy
Journal:  J Immunol       Date:  1988-02-01       Impact factor: 5.422

3.  The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus.

Authors:  R Grunow; S Jahn; T Porstmann; S S Kiessig; H Steinkellner; F Steindl; D Mattanovich; L Gürtler; F Deinhardt; H Katinger
Journal:  J Immunol Methods       Date:  1988-02-10       Impact factor: 2.303

4.  Human monoclonal antibody against a gag-coded protein of human immunodeficiency virus produced by a stable EBV-transformed cell clone.

Authors:  A Amadori; V Ciminale; M L Calabro; L Tessarollo; E Francavilla; L Chieco-Bianchi
Journal:  AIDS Res Hum Retroviruses       Date:  1989-02       Impact factor: 2.205

5.  Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers.

Authors:  P A Broliden; V Moschese; K Ljunggren; J Rosen; C Fundaro; A Plebani; M Jondal; P Rossi; B Wahren
Journal:  AIDS       Date:  1989-09       Impact factor: 4.177

6.  Mouse x human heterohybridomas as fusion partners with human B cell tumors.

Authors:  W L Carroll; K Thielemans; J Dilley; R Levy
Journal:  J Immunol Methods       Date:  1986-05-01       Impact factor: 2.303

7.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

8.  Human monoclonal antibody against glycoproteins of human immunodeficiency virus.

Authors:  T Sugano; Y Masuho; Y Matsumoto; D Lake; C Gschwind; E A Petersen; E M Hersh
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

9.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  Recent rubella virus infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; I Seppälä
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

View more
  3 in total

1.  Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.

Authors:  L T Chin; J Hinkula; M Levi; M Ohlin; B Wahren; C A Borrebaeck
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

2.  Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

Authors:  Tina Falkeborn; Andreas Bråve; Marie Larsson; Britt Akerlind; Ulf Schröder; Jorma Hinkula
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

3.  Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro.

Authors:  Claudia Devito; Rada Ellegård; Tina Falkeborn; Lennart Svensson; Mats Ohlin; Marie Larsson; Kristina Broliden; Jorma Hinkula
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.